UVA1 Light for Scleroderma and Similar Conditions
Stopped early · Not applicable
Conditions studied: Keloid, Scleroderma, Scars, Granuloma Annulare, Acne Keloidalis Nuchae
In brief
The purpose of this investigation is to evaluate the effectiveness of high-dose UVA1 irradiation in the treatment of fibrosing conditions of the skin, e.g., keloid (a thick scar from growth of fibrous tissue), scleroderma (deposits of fibrous tissue in the skin) and acne keloidalis nuchae (keloids on the back of the neck or hairline) old burn scars, granuloma annulare or other similar skin conditions. This UVA1 dosing schedule has been used successfully in Germany for various skin diseases, such as the above mentioned scleroderma.
Key facts
- Study ID
- NCT00476697
- Run by
- University of Michigan
- People needed
- 23
- Starts
- 1997-01-01
- Expected to finish
- 2003-07-01
- Last updated by the study team
- 2015-07-27
Who can join
Age: 10 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age: 10-80 years
- Clinical diagnosis of keloid (or hypertrophic scar), scleroderma, acne keloidalis nuchae, old burn scars, granuloma annulare, and other related conditions associated with altered dermal matrix.
- No disease states or physical conditions which would impair evaluation of the test site.
- Willing and able to receive UVA1 as directed in the protocol, make evaluation visits, and follow protocol restrictions.
- Signed, written, witnessed, informed consent form.
- Must live within driving distance of Ann Arbor, Michigan.
You may not qualify if…
- History of photosensitivity.
- Pregnant or nursing women.
- Systemic therapy for the fibrosing skin condition within 30 days prior to study enrollment.
- Involved in an investigational study within the previous 4 weeks.
Where it is running
- University of Michigan Department of Dermatology — Ann Arbor, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.